3-Mercaptopyruvic Acid - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

3-Mercaptopyruvic Acid

The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform

3-Mercaptopyruvic Acid – Free Register to Access Experts & Abstracts

Toshihiko Ubuka – One of the best experts on this subject based on the ideXlab platform.

Masahiro Kinuta – One of the best experts on this subject based on the ideXlab platform.

  • Identification ofS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-3-Mercaptopyruvic Acid with a metabolic intermediate betweenS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-l-cysteine andS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-3-mercaptolactic Acid
    Amino Acids, 1997
    Co-Authors: Masahiro Kinuta, H Shimizu, Natalie Masuoka, J. Ohta, Toshihiko Ubuka
    Abstract:

    S -[2-Carboxy-1-(1 H -imidazol-4-yl)ethyl]-3-Mercaptopyruvic Acid ( I ) was chemically synthesized in 15% yield by incubating a reaction mixture of trans -urocanic Acid and 3-fold excess of 3-Mercaptopyruvic Acid at 45°C for 6 days. The synthesized compound was characterized by fast-atom-bombardment mass spectrometry and high-voltage paper electrophoresis. Compound I was identified with a product of an enzymatic reaction of S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl]- l -cysteine ( II ) with rat liver homogenate in a phosphate buffer, pH 7.4. Compound I was degraded to S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl]-3-mercaptolactic Acid ( III ), a compound previously found in human urine [Kinuta et al. (1994) Biochem J 297: 475–478], by incubation with rat liver homogenate. From these results, we suggest that compound I is a metabolic intermediate for the formation of compound III from compound II . The present pathway follows a formation of compound II from S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl] gluthathione [Kinuta et al. (1993) Biochim Biophys Acta 1157: 192–198], a proposed metabolite of l -histidine.

J. Ohta – One of the best experts on this subject based on the ideXlab platform.

  • Identification ofS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-3-Mercaptopyruvic Acid with a metabolic intermediate betweenS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-l-cysteine andS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-3-mercaptolactic Acid
    Amino Acids, 1997
    Co-Authors: Masahiro Kinuta, H Shimizu, Natalie Masuoka, J. Ohta, Toshihiko Ubuka
    Abstract:

    S -[2-Carboxy-1-(1 H -imidazol-4-yl)ethyl]-3-Mercaptopyruvic Acid ( I ) was chemically synthesized in 15% yield by incubating a reaction mixture of trans -urocanic Acid and 3-fold excess of 3-Mercaptopyruvic Acid at 45°C for 6 days. The synthesized compound was characterized by fast-atom-bombardment mass spectrometry and high-voltage paper electrophoresis. Compound I was identified with a product of an enzymatic reaction of S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl]- l -cysteine ( II ) with rat liver homogenate in a phosphate buffer, pH 7.4. Compound I was degraded to S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl]-3-mercaptolactic Acid ( III ), a compound previously found in human urine [Kinuta et al. (1994) Biochem J 297: 475–478], by incubation with rat liver homogenate. From these results, we suggest that compound I is a metabolic intermediate for the formation of compound III from compound II . The present pathway follows a formation of compound II from S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl] gluthathione [Kinuta et al. (1993) Biochim Biophys Acta 1157: 192–198], a proposed metabolite of l -histidine.

Natalie Masuoka – One of the best experts on this subject based on the ideXlab platform.

  • Identification ofS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-3-Mercaptopyruvic Acid with a metabolic intermediate betweenS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-l-cysteine andS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-3-mercaptolactic Acid
    Amino Acids, 1997
    Co-Authors: Masahiro Kinuta, H Shimizu, Natalie Masuoka, J. Ohta, Toshihiko Ubuka
    Abstract:

    S -[2-Carboxy-1-(1 H -imidazol-4-yl)ethyl]-3-Mercaptopyruvic Acid ( I ) was chemically synthesized in 15% yield by incubating a reaction mixture of trans -urocanic Acid and 3-fold excess of 3-Mercaptopyruvic Acid at 45°C for 6 days. The synthesized compound was characterized by fast-atom-bombardment mass spectrometry and high-voltage paper electrophoresis. Compound I was identified with a product of an enzymatic reaction of S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl]- l -cysteine ( II ) with rat liver homogenate in a phosphate buffer, pH 7.4. Compound I was degraded to S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl]-3-mercaptolactic Acid ( III ), a compound previously found in human urine [Kinuta et al. (1994) Biochem J 297: 475–478], by incubation with rat liver homogenate. From these results, we suggest that compound I is a metabolic intermediate for the formation of compound III from compound II . The present pathway follows a formation of compound II from S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl] gluthathione [Kinuta et al. (1993) Biochim Biophys Acta 1157: 192–198], a proposed metabolite of l -histidine.

H Shimizu – One of the best experts on this subject based on the ideXlab platform.

  • Identification ofS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-3-Mercaptopyruvic Acid with a metabolic intermediate betweenS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-l-cysteine andS-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-3-mercaptolactic Acid
    Amino Acids, 1997
    Co-Authors: Masahiro Kinuta, H Shimizu, Natalie Masuoka, J. Ohta, Toshihiko Ubuka
    Abstract:

    S -[2-Carboxy-1-(1 H -imidazol-4-yl)ethyl]-3-Mercaptopyruvic Acid ( I ) was chemically synthesized in 15% yield by incubating a reaction mixture of trans -urocanic Acid and 3-fold excess of 3-Mercaptopyruvic Acid at 45°C for 6 days. The synthesized compound was characterized by fast-atom-bombardment mass spectrometry and high-voltage paper electrophoresis. Compound I was identified with a product of an enzymatic reaction of S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl]- l -cysteine ( II ) with rat liver homogenate in a phosphate buffer, pH 7.4. Compound I was degraded to S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl]-3-mercaptolactic Acid ( III ), a compound previously found in human urine [Kinuta et al. (1994) Biochem J 297: 475–478], by incubation with rat liver homogenate. From these results, we suggest that compound I is a metabolic intermediate for the formation of compound III from compound II . The present pathway follows a formation of compound II from S -[2-carboxy-1-(1 H -imidazol-4-yl)ethyl] gluthathione [Kinuta et al. (1993) Biochim Biophys Acta 1157: 192–198], a proposed metabolite of l -histidine.